Reports
Reports
Analyst Viewpoint
Growth in incidence of osteoarthritis and rise in geriatric population are fueling the osteoarthritis drugs market development. Advancements in medical research and pharmaceutical development are likely to offer lucrative opportunities to vendors in the osteoarthritis drugs industry landscape.
Companies in the market are exploring ways to devise asymptomatic osteoarthritis drugs, which would provide a preventive care in the long run. They are developing and commercializing injectable resiniferatoxin for osteoarthritis of the knee.
The ongoing efforts within the pharmaceutical sector to address the unmet medical needs of osteoarthritis patients and improve their quality of life are driving the osteoarthritis drugs market trajectory.
Osteoarthritis, better known as degenerative joint disease, majorly impacts the neck, knees, hips, lower back, and small joints of fingers. The disease progresses gradually, which results in moderate to severe pain in the body parts mentioned above, and low quality of life, especially in the population subject to low physical activity or the one with higher body mass index (BMI).
Oral, topical, and parenteral pain medications are broadly used for managing pain associated with osteoarthritis. Research states that oral analgesics, topical agents, intra-articular agents, and nutraceuticals offer 30% reduction in pain due to osteoarthritis.
The ongoing trend is that of devising personalized medicines for osteoarthritis. Essential features about biomarkers that would have clinical relevance regarding the personalized approach to therapy include acceptable levels of specificity and sensitivity, ease of measurement, and test methods interpretable by the clinicians.
This concept of personalization of medicines is expected to be one of the factors driving the osteoarthritis drugs market demand.Using prescription NSAIDs and OTC causes side effects such as adverse cardiovascular events.
Cyclooxygenase (COX)-2 selective NSAIDs (coxibs) as well as non-selective NSAIDs increase the risk of cardiovascular diseases in patients. This factor is likely to restrain the osteoarthritis drugs market opportunities during the forecast period.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
A noticeable increase in the obese population, and, in turn, the population affected by osteoarthritis, is expected to drive the osteoarthritis pharmaceuticals market size during the forecast period.
The modern-day sedentary lifestyle has raised the obesity quotient (OQ) globally. This, in turn, results in exerting excessive pressure on hips and knees, which is likely to affect cushion joints for breaking down faster.
CDC, in May 2022, released a report stating that the prevalence of obesity was 39.8% amongst those aged between 20 and 39, 41.5$ amongst those aged 60 and above, and 44.3% amongst adults aged between 40 and 59. It further states that The U.S. witnessed increase in incidence of obesity to 41.9% from 30.5% between March 2019 and March 2020.
The older population is more prone to osteoarthritis as aging alterations in musculoskeletal system raise propensity to osteoarthritis. Additionally, joints affected are generally related to other osteoarthritis risk factors such as genetics, obesity, joint injury.
As per the data published by the UN in 2022, 16% of the global population will cross 65 by the year 2050. Moreover, PubMed Central had published an article in September 2022 stating that osteoarthritis is the prime cause of disability amongst the geriatric population. Need to treat this sizable population is driving the osteoarthritis drugs market growth.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America held the largest osteoarthritis drugs market share in 2022. The region is expected to continue with its dominance even during the forecast period. Rise in prevalence of osteoarthritis is fueling the market dynamics of the region.
As per the National Public health Agenda report for Osteoarthritis 2020, osteoarthritis affects nearly 32.5 million people in the U.S. As per data published by Arthritis Society Canada in September 2021, over 4 million Canadians are suffering from osteoarthritis.
Europe’s osteoarthritis drugs industry growth can be ascribed to more than 54 million people in Western Europe suffering from osteoarthritis, as stated by Osteoarthritis Europe. It further states that joint replacement surgery is preferred by majority of patients in the region. High incidence of osteoarthritis is boosting the osteoarthritis therapeutics market in Asia Pacific.
Companies are engaging in extensive R&D to stay affable. For instance, in September 2020, Sorrento Therapeutics, Inc. published positive Phase 1b trial data of resiniferatoxin (RTX) with 84-day end-point analysis for all the patients with negligible safety signals. RTX helps when patients do not respond to opioids.
Vendors are introducing medications based on symptoms. For instance, GlaxoSmithKline, in 2020 introduced Voltaren in the U.S. Novartis, in September 2021, received approval from the U.S. FDA for LNA043 as a potential first-in-class ailment modifying treatment for OA.
Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc., Chugai Pharmaceutical Industries Ltd., Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc. are some of the key players in this market.
These companies have been profiled in the osteoarthritis drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 8.6 Bn |
| Market Forecast (Value) in 2031 | US$ 17.7 Bn |
| Growth Rate (CAGR) | 8.5% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 8.6 Bn in 2022
It is projected to grow at a CAGR of 8.5% from 2023 to 2031
Growing incidences of rheumatoid arthritis and rise in geriatric population
Hospitals accounted for the largest share in 2022
North America was the dominant region in osteoarthritis drugs market in 2022
Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc., Chugai Pharmaceutical Industries Ltd., Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Osteoarthritis Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Corticosteroids
6.3.2. NSAIDs & Others
6.3.3. Viscosupplementation Agents
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Osteoarthritis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Corticosteroids
10.3.2. NSAIDs & Others
10.3.3. Viscosupplementation Agents
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Parenteral
10.4.3. Topical
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Osteoarthritis Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Corticosteroids
11.3.2. NSAIDs & Others
11.3.3. Viscosupplementation Agents
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Topical
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Corticosteroids
12.3.2. NSAIDs & Others
12.3.3. Viscosupplementation Agents
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Topical
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Corticosteroids
13.3.2. NSAIDs & Others
13.3.3. Viscosupplementation Agents
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Topical
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Corticosteroids
14.3.2. NSAIDs & Others
14.3.3. Viscosupplementation Agents
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Topical
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Horizon Pharma plc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Anika Therapeutics, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ferring B.V.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bioventus, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Chugai Pharmaceutical Industries Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Alkem Laboratories
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Flexion Therapeutics, Inc.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Zimmer Biomet Holdings, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 07: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 08: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 11: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 12: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 24: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Osteoarthritis Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global Osteoarthritis Drugs Market Value Share, by Drug Class, 2022
Figure 04: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 05: Global Osteoarthritis Drugs Market Value Share, by Route of Administration, 2022
Figure 06: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Osteoarthritis Drugs Market Value Share, by Distribution Channel, 2022
Figure 08: Global Osteoarthritis Drugs Market Value Share, by Region, 2022
Figure 09: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 11: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 12: Global Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 13: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 14: Global Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 15: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 16: Global Osteoarthritis Drugs Market Value Share Analysis, by Region, 2022–2031
Figure 17: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Region, 2023–2031
Figure 18: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Osteoarthritis Drugs Market Value Share Analysis, by Country, 2022–2031
Figure 21: North America Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 22: North America Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 23: North America Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 24: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 25: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 26: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 30: Europe Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 31: Europe Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 32: Europe Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 33: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 34: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 35: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 39: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 40: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 41: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 42: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 43: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 44: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 48: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 49: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 50: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 51: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 52: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 53: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 57: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 58: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 59: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 60: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 61: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 62: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Osteoarthritis Drugs Market